Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dina Stroopinsky

Showing results (11-20 of 32) with videos related to

Pageof 4
Sort By:
Molecular Cancer Therapeutics|July 22, 2017
Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell LymphomaSalvia Jain, Abigail Washington, Rebecca Karp Leaf, et al.
Cancer Immunology, Immunotherapy : CII|June 27, 2012
Lenalidomide enhances anti-myeloma cellular immunityKatarina Luptakova, Jacalyn Rosenblatt, Brett Glotzbecker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2020
Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth <i>In Vitro</i> and <i>In Vivo</i>Eleni Anastasiadou, Anita G Seto, Xuan Beatty, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 30, 2017
DCOne as an Allogeneic Cell-based Vaccine for Multiple MyelomaRebecca Karp Leaf, Dina Stroopinsky, Athalia R Pyzer, et al.
Blood|June 7, 2015
Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphomaSalvia Jain, Dina Stroopinsky, Li Yin, et al.
Cancer Research|July 23, 2013
MUC1 is a potential target for the treatment of acute myeloid leukemia stem cellsDina Stroopinsky, Jacalyn Rosenblatt, Keisuke Ito, et al.
British Journal of Haematology|January 21, 2017
Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1Michal Bar-Natan, Dina Stroopinsky, Katarina Luptakova, et al.
Journal of Cellular and Molecular Medicine|May 16, 2018
MUC1-C drives myeloid leukaemogenesis and resistance to treatment by a survivin-mediated mechanismDina Stroopinsky, Hasan Rajabi, Myrna Nahas, et al.
American Journal of Hematology|November 10, 2017
A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemiaDaniel J DeAngelo, Andrew M Brunner, Lillian Werner, et al.
British Journal of Haematology|March 5, 2019
Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell/AML vaccineMyrna R Nahas, Dina Stroopinsky, Jacalyn Rosenblatt, et al.
Pageof 4

Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
Molecular Cancer Therapeutics|July 22, 2017
Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell LymphomaSalvia Jain, Abigail Washington, Rebecca Karp Leaf, et al.
Cancer Immunology, Immunotherapy : CII|June 27, 2012
Lenalidomide enhances anti-myeloma cellular immunityKatarina Luptakova, Jacalyn Rosenblatt, Brett Glotzbecker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2020
Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth <i>In Vitro</i> and <i>In Vivo</i>Eleni Anastasiadou, Anita G Seto, Xuan Beatty, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 30, 2017
DCOne as an Allogeneic Cell-based Vaccine for Multiple MyelomaRebecca Karp Leaf, Dina Stroopinsky, Athalia R Pyzer, et al.
Blood|June 7, 2015
Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphomaSalvia Jain, Dina Stroopinsky, Li Yin, et al.
Cancer Research|July 23, 2013
MUC1 is a potential target for the treatment of acute myeloid leukemia stem cellsDina Stroopinsky, Jacalyn Rosenblatt, Keisuke Ito, et al.
British Journal of Haematology|January 21, 2017
Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1Michal Bar-Natan, Dina Stroopinsky, Katarina Luptakova, et al.
Journal of Cellular and Molecular Medicine|May 16, 2018
MUC1-C drives myeloid leukaemogenesis and resistance to treatment by a survivin-mediated mechanismDina Stroopinsky, Hasan Rajabi, Myrna Nahas, et al.
American Journal of Hematology|November 10, 2017
A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemiaDaniel J DeAngelo, Andrew M Brunner, Lillian Werner, et al.
British Journal of Haematology|March 5, 2019
Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell/AML vaccineMyrna R Nahas, Dina Stroopinsky, Jacalyn Rosenblatt, et al.
Pageof 4